Compare DSY & NOTV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | DSY | NOTV |
|---|---|---|
| Founded | 2020 | 1974 |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 39.9M | 29.9M |
| IPO Year | N/A | 1997 |
| Metric | DSY | NOTV |
|---|---|---|
| Price | $0.42 | $0.80 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $3.00 |
| AVG Volume (30 Days) | 130.0K | ★ 1.6M |
| Earning Date | 01-01-0001 | 12-03-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 120.37 | N/A |
| EPS | ★ 0.01 | N/A |
| Revenue | $7,323,356.00 | ★ $513,024,000.00 |
| Revenue This Year | N/A | $6.26 |
| Revenue Next Year | N/A | $45.49 |
| P/E Ratio | $34.08 | ★ N/A |
| Revenue Growth | ★ 16.37 | 4.54 |
| 52 Week Low | $0.40 | $0.66 |
| 52 Week High | $7.33 | $6.48 |
| Indicator | DSY | NOTV |
|---|---|---|
| Relative Strength Index (RSI) | 23.28 | 36.67 |
| Support Level | $0.40 | $0.84 |
| Resistance Level | $0.48 | $0.95 |
| Average True Range (ATR) | 0.02 | 0.12 |
| MACD | 0.01 | 0.02 |
| Stochastic Oscillator | 7.84 | 39.36 |
Big Tree Cloud Holdings Ltd is a consumer-oriented, mission-driven, and technology-empowered company engaged in the development, production, distribution, and sales of personal care products and other consumer goods. Operating under a consumer-to-manufacturer and merchant (C2M) model, the company integrates online and offline operations to enhance customer engagement, product innovation, and marketing efficiency. Specializing in feminine hygiene products such as sterilized feminine pads, menstrual pants, and related items, Big Tree Cloud leverages its platform to consolidate resources within China's personal care industry while building a consumer community that provides direct feedback and product insights.
Inotiv Inc is a pharmaceutical development company specializing in nonclinical and analytical drug discovery, development services to the pharmaceutical, chemical, and medical device industries. It operates in two segments; Discovery and Safety Assessment (DSA) and Research Models and Services (RMS). Through the DSA segment, the company supports the discovery, nonclinical development, and clinical development needs of researchers and clinicians for small molecule drug candidates, biotherapeutics, and biomedical devices. Through the RMS segment, the company offers access to a wide range of small and large research models for basic research, drug discovery, development, and specialized models for specific diseases and therapeutic areas. The company earns maximum revenue from RMS Segment.